Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split ...
Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...